Trevi Therapeutics, Inc. Operating Lease Cost
Trevi Therapeutics, Inc. (TRVI) reported Operating Lease Cost of $342.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-17
- Trevi Therapeutics, Inc. operating lease, cost for the quarter ending 2025-12-31 was $85.00K, a 0.00% change year-over-year.
- Trevi Therapeutics, Inc. operating lease, cost for the quarter ending 2025-09-30 was $86.00K, a 1.18% increase year-over-year.
- Trevi Therapeutics, Inc. operating lease, cost for the quarter ending 2025-06-30 was $86.00K, a 1.18% increase year-over-year.
- Trevi Therapeutics, Inc. operating lease, cost for the quarter ending 2025-03-31 was $85.00K, a 0.00% change year-over-year.
- Trevi Therapeutics, Inc. operating lease, cost for fiscal 2025 was $342.00K, a 0.29% increase from fiscal 2024.
- Trevi Therapeutics, Inc. operating lease, cost for fiscal 2024 was $341.00K, a 18.82% increase from fiscal 2023.
- Trevi Therapeutics, Inc. operating lease, cost for fiscal 2023 was $287.00K, a 133.33% increase from fiscal 2022.
- Trevi Therapeutics, Inc. operating lease, cost for fiscal 2022 was $123.00K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $171.00K derived: sum of 2 quarters · filed 2026-03-17 | $257.00K derived: sum of 3 quarters · filed 2026-03-17 | $342.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | $86.00K 10-Q · filed 2025-11-13 | $172.00K derived: sum of 2 quarters · filed 2025-11-13 | $257.00K 10-Q · filed 2025-11-13 | $342.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-06-30 | $86.00K 10-Q · filed 2025-08-07 | $171.00K 10-Q · filed 2025-08-07 | $256.00K derived: sum of 3 quarters · filed 2026-03-17 | $341.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-03-31 | $85.00K 10-Q · filed 2025-05-08 | $170.00K derived: sum of 2 quarters · filed 2026-03-17 | $255.00K derived: sum of 3 quarters · filed 2026-03-17 | $340.00K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $170.00K derived: sum of 2 quarters · filed 2026-03-17 | $255.00K derived: sum of 3 quarters · filed 2026-03-17 | $341.00K 10-K · filed 2026-03-17 |
| 2024-09-30 | $85.00K 10-Q · filed 2025-11-13 | $170.00K derived: sum of 2 quarters · filed 2025-11-13 | $256.00K 10-Q · filed 2025-11-13 | $340.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $85.00K 10-Q · filed 2025-08-07 | $170.00K 10-Q · filed 2025-08-07 | $255.00K derived: sum of 3 quarters · filed 2025-08-07 | $340.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $85.00K 10-Q · filed 2025-05-08 | $170.00K derived: sum of 2 quarters · filed 2025-05-08 | $255.00K derived: sum of 3 quarters · filed 2025-05-08 | $340.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $170.00K derived: sum of 2 quarters · filed 2025-03-18 | $255.00K derived: sum of 3 quarters · filed 2025-03-18 | $287.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | $85.00K 10-Q · filed 2024-11-06 | $170.00K derived: sum of 2 quarters · filed 2024-11-06 | $202.00K 10-Q · filed 2024-11-06 | $232.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $85.00K 10-Q · filed 2024-08-08 | $117.00K 10-Q · filed 2024-08-08 | $147.00K derived: sum of 3 quarters · filed 2024-08-08 | $178.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $31.00K 10-Q · filed 2024-05-07 | $62.00K derived: sum of 2 quarters · filed 2024-05-07 | $93.00K derived: sum of 3 quarters · filed 2024-05-07 | $116.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $62.00K derived: sum of 2 quarters · filed 2024-03-20 | $85.00K derived: sum of 3 quarters · filed 2024-03-20 | $123.00K 10-K · filed 2024-03-20 |
| 2022-09-30 | $31.00K 10-Q · filed 2023-11-09 | $54.00K derived: sum of 2 quarters · filed 2023-11-09 | $92.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $23.00K 10-Q · filed 2023-08-10 | $61.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $39.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |